Type 2 diabetes

Eli Lilly's experimental drug retatrutide helped people with type 2 diabetes lose around 21% of their body weight in a clinical trial, according to Reuters. The injectable, which targets multiple hormones, is being closely watched as a potential next-generation obesity treatment following the success of tirzepatide and semaglutide.